ANTISYNTHETASE SYNDROME
Clinical trials for ANTISYNTHETASE SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ANTISYNTHETASE SYNDROME trials appear
Sign up with your email to follow new studies for ANTISYNTHETASE SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Matched conditions: ANTISYNTHETASE SYNDROME
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare lung disease: JAK inhibitors vs standard care
Disease control Recruiting nowThis study tests whether JAK inhibitors work better than calcineurin inhibitors as the first treatment for lung scarring in people with antisynthetase syndrome. About 80 adults with active lung disease will be followed for 12 months to see which drug improves breathing and surviv…
Matched conditions: ANTISYNTHETASE SYNDROME
Phase: NA • Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Engineered immune cells take on rare muscle disorders
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and red…
Matched conditions: ANTISYNTHETASE SYNDROME
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC